P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis," published in the November 2024 issue of Gastroenterology by Hu et al. Since 2015, CT-P13, a ...

Researchers using machine learning discovered that variations in microbial load in the gut, influenced by age, sex, diet, and ...

Nanoparticles that turn inflammation into propulsion power deliver targeted IBD treatment, enhancing precision and efficacy.

Medically reviewed by Kumkum Sarkar Patel, MD Crohn’s disease is an inflammatory bowel disease (IBD) that impacts your ...

Colorectal surgeons evaluated the treatments available for patients with hemorrhoids at a conference in France.

Approximately three million Americans have inflammatory bowel disease. IBD is an umbrella term for Crohn's disease and ulcerative colitis, illnesses marked by chronic or repeated bouts of inflammation ...

The underlying cause of inflammatory bowel disease (Crohn’s and ulcerative colitis) still isn’t well-understood. Although ...

Subsequent treatment should be initiated that is evidence-based ... grant (1S06023N); Fonds Wetenschappelijk Onderzoek, and ...

A randomized controlled trial finds no clear benefit of adding bezlotoxumab to FMT in patients with IBD and recurrent C difficile infection.

The digestive system plays an essential role in human health by managing nutrient intake, energy absorption, and waste excretion. Disorders within this system can lead to malnutrition and energy ...

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the treatment process.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious ...